EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Hyperhomocysteinemia on Valve Calcification and Prognosis in Rheumatic Mitral Valve Surgery

Songhao Jia, Peiyi Liu, Maozhou Wang, Hongkai Zhang, Tingting Liu iD, Xian Yang iD, Ruihan Jia iD, Xiaoyan Hao iD, Xiaohan Zhong, Meili Wang, Wei Luo, Yihua He iD und 4 weitere

Cardiovascular Therapeutics · 2025

DOI: 10.1155/cdr/5833541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Songhao Jia und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, ccmu.edu.cn. Hauptthemen laut MEDLINE: Hyperhomocysteinemia, Rheumatic Heart Disease, Mitral Valve Stenosis, Mitral Valve. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project, Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hyperhomocysteinemia is a risk factor for cardiovascular disease, but its impact on valve disease is lacking in research. This study was aimed at investigating the impact of hyperhomocysteinemia on rheumatic mitral valve calcification and prognosis in patients undergoing surgery.

Methods

This study included 672 patients with severe rheumatic mitral valve stenosis who underwent surgery between January 2016 and December 2022. Patients were stratified by preoperative homocysteine levels. Mitral valve pathology was assessed by echocardiography and coronary CTA, with all‐cause mortality as the primary mid‐term endpoint.

Results

Among this surgical cohort of 672 patients with severe rheumatic mitral stenosis, 208 (31.0%) patients were identified with hyperhomocysteinemia. Imaging assessment revealed that these patients had a higher Agatston score for mitral valve calcification (37.47 vs. 17.19, p = 0.038) after adjusting baseline data. Restricted cubic splines revealed a significant dose–response relationship, with mitral valve calcification increasing progressively with higher homocysteine levels ( p < 0.001). The Kaplan–Meier survival analysis showed that patients with hyperhomocysteinemia had significantly lower mid‐term survival rates (log‐rank p = 0.004). Through univariate and multivariate COX regression analyses, it was found that hyperhomocysteinemia was an independent risk factor affecting mid‐term postoperative survival (HR, 2.257; p = 0.048).

Conclusions

In patients undergoing surgery for rheumatic heart disease, hyperhomocysteinemia was associated with the formation of rheumatic mitral valve calcification and increased mid‐term postoperative mortality. Trial Registration: Chinese Clinical Trial Registry identifier ChiCTR2200067151

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperhomocysteinemiaRheumatic Heart DiseaseMitral Valve StenosisMitral ValveHomocysteineCalcinosisCardiac Surgical ProceduresHumansFemaleMaleRisk FactorsMiddle AgedTime FactorsAdultTreatment OutcomeBiomarkersRisk AssessmentRetrospective StudiesSeverity of Illness IndexAged

Stichwörter der Autor:innen

hyperhomocysteinemiamitral valve calcificationprognosisrheumatic heart disease

Substanzen

HomocysteineBiomarkers

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, ccmu.edu.cn.
  • Beijing Laboratory of Cardiovascular Precision Medicine, Beijing Municipal Education Commission, Beijing, China.
  • Key Lab of Medical Engineering for Cardiovascular Disease, Ministry of Education, Beijing, China, moe.edu.cn.
  • Laboratory for Clinical Medicine, Capital Medical University, Beijing, China, ccmu.edu.cn.
  • Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, ccmu.edu.cn.
  • Echocardiography Medical Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China, ccmu.edu.cn.

ORCID-Profile: Tingting Liu, Xian Yang, Ruihan Jia, Xiaoyan Hao, Yihua He, Hongjia Zhang, Wenjian Jiang

Förderung

  • National Science and Technology Major Project
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Jia, S., Liu, P., Wang, M., Zhang, H., Liu, T., Yang, X., Jia, R., Hao, X., Zhong, X., Wang, M., Luo, W., He, Y., Xu, L., Meng, X., Zhang, H., & Jiang, W. (2025). Impact of Hyperhomocysteinemia on Valve Calcification and Prognosis in Rheumatic Mitral Valve Surgery. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/5833541

Vancouver

Jia S, Liu P, Wang M, Zhang H, Liu T, Yang X, et al. Impact of Hyperhomocysteinemia on Valve Calcification and Prognosis in Rheumatic Mitral Valve Surgery. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/5833541

BibTeX
@article{Jia2025,
  author = {Jia, Songhao and Liu, Peiyi and Wang, Maozhou and Zhang, Hongkai and Liu, Tingting and Yang, Xian and Jia, Ruihan and Hao, Xiaoyan and Zhong, Xiaohan and Wang, Meili and Luo, Wei and He, Yihua and Xu, Lei and Meng, Xu and Zhang, Hongjia and Jiang, Wenjian},
  title = {Impact of Hyperhomocysteinemia on Valve Calcification and Prognosis in Rheumatic Mitral Valve Surgery},
  journal = {Cardiovascular Therapeutics},
  year = {2025},
  doi = {10.1155/cdr/5833541}
}
Kostenlos starten →